Economic evaluation of a hospital-initiated intervention for smokers with chronic disease, in Ontario, Canada

Kerri-Anne Mullen,1 Douglas Coyle,2 Douglas Manuel,3 Hai V Nguyen,4 Ba’ Pham,5 Andrew L Pipe,1 Robert D Reid1

ABSTRACT

Introduction Cigarette smoking causes many chronic diseases that are costly and result in frequent hospitalisation. Hospital-initiated smoking cessation interventions increase the likelihood that patients will become smoke-free. We modelled the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counselling, pharmacotherapy and posthospital follow-up, compared to usual care among smokers hospitalised with acute myocardial infarction (AMI), unstable angina (UA), heart failure (HF), and chronic obstructive pulmonary disease (COPD).

Methods We completed a cost-effectiveness analysis based on a decision-analytic model to assess smokers hospitalised in Ontario, Canada for AMI, UA, HF, and COPD, their risk of continuing to smoke and the effects of quitting on re-hospitalisation and mortality over a 1-year period. We calculated short-term and long-term cost-effectiveness ratios. Our primary outcome was 1-year cost per quality-adjusted life year (QALY) gained. Results From the hospital payer’s perspective, delivery of the OMSC can be considered cost effective with 1-year cost per QALY gained of $C138 6, and lifetime cost per QALY gained of $C6 8. In the first year, we calculated that provision of the OMSC to 15 326 smokers would generate 4689 quitters, and would prevent 116 rehospitalisations, 923 hospital days, and 119 deaths. Results were robust within numerous sensitivity analyses.

Discussion The OMSC appears to be cost-effective from the hospital payer perspective. Important consideration is the relatively low intervention cost compared to the reduction in costs related to readmissions for illnesses associated with continued smoking.

INTRODUCTION

Smoking-related illnesses are principal drivers of healthcare spending; they are estimated to contribute up to 15% of healthcare expenditures in developed nations.1 Many of the chronic diseases caused by cigarette smoking result in frequent hospitalisation making the hospital an ideal setting to initiate cessation treatment.2 Rigotti and colleagues recently updated a review and meta-analysis of studies examining the efficacy of hospital-initiated smoking cessation interventions. The interventions included in the review were offered by hospital staff (eg, physicians, nurses, or other allied health professionals), and could involve the provision of advice, intensive counselling, pharmacotherapy and follow-up contact after hospital discharge. The authors concluded that smoking cessation support that began in hospital and continued for at least 1 month after discharge significantly increased the likelihood of patients being smoke-free in the long term (risk ratio=1.37, 95% CI 1.27 to 1.48; 23 trials), and that strategies that included counselling and pharmacotherapy were more efficacious than just counselling alone (relative risks (RR)=1.54, 95% CI 1.34 to 1.79, six trials).3

One of the studies included in the Rigotti review was by researchers at the University of Ottawa Heart Institute, of an intervention that is now known as the Ottawa Model for Smoking Cessation (OMSC).4 The OMSC is a systematic approach to the identification, treatment and follow-up of smokers that is embedded within hospital management systems using organisational change strategies. The OMSC has been found to significantly increase long-term cessation rates by an absolute 15% (from 29% to 44%) in cardiac patients, and by 11% (from 18% to 29%) in general hospital populations.4 5

Patients who quit smoking during hospitalisation are less likely to be rehospitalised or to die during follow-up.6 7 Despite such evidence, most hospitals fail to deliver cessation interventions due, in part, to concerns about the perceived costs of such programmes. Economic evaluations are becoming increasingly popular in helping healthcare administrators choose whether or not to fund interventions, and where to devote resources.8 Cost-effectiveness analysis (CEA) is a type of economic evaluation that examines the consequences or gains of an intervention compared to an alternative. The results of CEA are expressed as cost-effectiveness ratios. For example, outcomes of CEA for a smoking cessation programme might include the cost per number of people who quit smoking, cost per number of hospital-days prevented by the programme, or cost per number of years of life gained by the programme. Cost-utility analysis (CUA) is a form of CEA that examines the cost of an intervention relative to the benefit it produces in terms of the number of years of life gained, combined with the quality of those years lived. The quality-adjusted life-year (QALY) is the most common outcome measured in a CUA; it is a cost-effectiveness ratio that takes into account quantity and health-related quality of life.9

The purpose of this study was to determine, from the hospital payer’s perspective, the short-term (1 year) and long-term (lifetime) cost-effectiveness.
of the OMSC intervention, as compared to a usual care condition, among smokers hospitalised with acute myocardial infarction (AMI), unstable angina (UA), heart failure (HF), or chronic obstructive pulmonary disease (COPD). This perspective and these four diagnoses were selected for our analysis due to the particular burden of these tobacco-related diseases on hospitalisation and rehospitalisation, and the availability of data.

**METHODS**

**Setting**

Our study examined patients hospitalised in Ontario, a Canadian province with a population of approximately 12.8 million. The smoking prevalence among Ontarians aged 15 years and older was 15.4% in 2009.10 The smoking prevalence among Canadian smokers aged 15 years and older is higher, at 20%;11 consequently, on a given day in Ontario, approximately 6400 of the province’s 32 000 hospital beds are occupied by current smokers. Healthcare is publicly funded through the Ontario Health Insurance Plan, where medically necessary services including primary care and specialty care, hospital stays, diagnostic investigations and surgical procedures are available at no cost to residents. There are 211 hospital sites in Ontario that recorded an estimated 987 757 acute care inpatient admissions in 2009.12

**Population**

Our analysis included smokers hospitalised for one of the four selected diagnoses. In 2009, there were 20 503, 5370, 16 339 and 17 585 unique admissions to Ontario hospitals for AMI, UA, HF and COPD, respectively, for a total of 59 797, as reported by the Canadian Institute for Health Information’s (CIHI) Discharge Abstract Database (DAD).13 We combined data from a previously published quasi-experimental, before and after cohort study of the OMSC conducted at nine Ontario hospitals,5 with data from similar evaluations that took place at an additional 19 Ontario hospitals, in order to estimate the number of these unique admissions that involved smokers, and to estimate programme quit rates. Our study dataset included patients (n=3269) aged 18 years or older who were hospitalised for either AMI (n=750), UA (n=705), HF (n=835), or COPD (n=936). Smokers were defined as anyone who reported having smoked daily (≥1 cigarette per day) in the 6 months leading up to their hospitalisation. The overall smoking prevalence was 25.4%; disease-specific smoking rates are displayed in table 1. Applying the disease-specific smoking prevalence to the number of unique admissions, we estimated that 15 326 smokers were hospitalised in 2009 for AMI (n=5194), UA (n=1424), HF (n=2804), and COPD (n=5904).

### Table 1  Data elements included in the base case analysis ($ in $C)

<table>
<thead>
<tr>
<th></th>
<th>AMI</th>
<th>UA</th>
<th>HF</th>
<th>COPD</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking prevalence rates (95% CI)</td>
<td>0.25 (0.22 to 0.29)</td>
<td>0.27 (0.23 to 0.30)</td>
<td>0.17 (0.14 to 0.21)</td>
<td>0.34 (0.29 to 0.38)</td>
<td>5</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>56.9 (10.2)</td>
<td>58.0 (10.5)</td>
<td>60.8 (13.0)</td>
<td>62.3 (15.4)</td>
<td>5</td>
</tr>
<tr>
<td>Usual care</td>
<td>57.4 (13.1)</td>
<td>56.6 (12.9)</td>
<td>61.4 (10.4)</td>
<td>65.9 (10.6)</td>
<td>5</td>
</tr>
<tr>
<td>12-month smoking abstinence rates (95% CI)</td>
<td>0.22 (0.15 to 0.30)</td>
<td>0.20 (0.13 to 0.30)</td>
<td>0.17 (0.10 to 0.27)</td>
<td>0.13 (0.08 to 0.21)</td>
<td>5</td>
</tr>
<tr>
<td>Usual care</td>
<td>0.38 (0.28 to 0.51)</td>
<td>0.35 (0.25 to 0.48)</td>
<td>0.28 (0.20 to 0.39)</td>
<td>0.24 (0.19 to 0.30)</td>
<td>5</td>
</tr>
<tr>
<td>Risk of one rehospitalisation in first year (95% CI)</td>
<td>0.05 (0.03 to 0.06)</td>
<td>0.10 (0.09 to 0.12)</td>
<td>0.17 (0.16 to 0.19)</td>
<td>0.18 (0.17 to 0.20)</td>
<td>7, 17-20</td>
</tr>
<tr>
<td>Quit smoking</td>
<td>0.04 (0.03 to 0.05)</td>
<td>0.08 (0.07 to 0.10)</td>
<td>0.14 (0.13 to 0.16)</td>
<td>0.15 (0.14 to 0.16)</td>
<td>7, 17-20</td>
</tr>
<tr>
<td>Risk of two or more rehospitalisations in first year (95% CI)</td>
<td>0.03 (0.02 to 0.04)</td>
<td>0.03 (0.02 to 0.05)</td>
<td>0.09 (0.07 to 0.11)</td>
<td>0.14 (0.12 to 0.15)</td>
<td>7, 17-20</td>
</tr>
<tr>
<td>Continue to smoke</td>
<td>0.02 (0.01 to 0.04)</td>
<td>0.03 (0.01 to 0.04)</td>
<td>0.08 (0.06 to 0.09)</td>
<td>0.11 (0.10 to 0.13)</td>
<td>21</td>
</tr>
<tr>
<td>Quot smoking</td>
<td>$9559 ($14 539)</td>
<td>$5950 ($6932)</td>
<td>$10 029 ($16 696)</td>
<td>$8808 ($16 795)</td>
<td>5</td>
</tr>
<tr>
<td>Length of stay of rehospitalisation (days), mean (SD)</td>
<td>5.6 (9.8)</td>
<td>4.1 (4.9)</td>
<td>9.7 (12.8)</td>
<td>8.4 (14.5)</td>
<td>21</td>
</tr>
<tr>
<td>Risk of death in first year (95% CI)</td>
<td>0.14 (0.13 to 0.15)</td>
<td>0.09 (0.08 to 0.10)</td>
<td>0.48 (0.47 to 0.49)</td>
<td>0.09 (0.09 to 0.09)</td>
<td>19, 20, 22-25</td>
</tr>
<tr>
<td>Quit smoking</td>
<td>0.09 (0.08 to 0.10)</td>
<td>0.06 (0.05 to 0.07)</td>
<td>0.31 (0.30 to 0.31)</td>
<td>0.06 (0.06 to 0.06)</td>
<td>26, 27</td>
</tr>
<tr>
<td>Utility scores</td>
<td>0.53</td>
<td>0.52</td>
<td>0.48</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Continue to smoke</td>
<td>0.55</td>
<td>0.54</td>
<td>0.50</td>
<td>0.52</td>
<td></td>
</tr>
<tr>
<td>Life expectancy, mean number of years remaining</td>
<td>7.58</td>
<td>7.42</td>
<td>5.19</td>
<td>7.75</td>
<td>28, 30</td>
</tr>
<tr>
<td>Continue to smoke</td>
<td>8.76</td>
<td>8.64</td>
<td>6.07</td>
<td>9.01</td>
<td></td>
</tr>
<tr>
<td>Quit smoking</td>
<td>$20.63</td>
<td>$20.63</td>
<td>$20.63</td>
<td>$20.63</td>
<td></td>
</tr>
<tr>
<td>Intervention costs (per patient)</td>
<td>$13.95*</td>
<td>$9.23*</td>
<td>$21.60*</td>
<td>$21.25*</td>
<td></td>
</tr>
<tr>
<td>Personnel costs to complete in-hospital consultation</td>
<td>$10.30</td>
<td>$10.30</td>
<td>$10.30</td>
<td>$10.30</td>
<td></td>
</tr>
<tr>
<td>Automated follow-up system fee</td>
<td>$27.24</td>
<td>$27.24</td>
<td>$27.24</td>
<td>$27.24</td>
<td></td>
</tr>
<tr>
<td>Total intervention cost</td>
<td>$71.50</td>
<td>$66.98</td>
<td>$78.81</td>
<td>$76.44</td>
<td></td>
</tr>
</tbody>
</table>

*Pharmacotherapy costs differ by diagnosis due to differing mean lengths of stay (LOS): AMI, mean LOS 5.6 days; UA, mean LOS 4.1 days; HF, mean LOS 9.7 days; COPD, mean LOS 8.4 days.

AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; HF, heart failure; OMSC, Ottawa model for smoking cessation; UA, unstable angina pectoris.
**Intervention**

The OMSC was selected as the intervention in our model for several reasons. It is the most widely implemented hospital-initiated smoking cessation intervention in Canada. As of 2014, it had been implemented in approximately 100 (14%) Canadian hospitals. It features a large programme database where data were available to generate some of our model’s data elements, broken down by disease group. A Canadian intervention was preferred as our estimates of cost and risk of rehospitalisation were derived from Canadian sources.

As part of the OMSC intervention, the following takes places with each admitted smoker: (1) a 10–30 min consultation is completed by a nurse or another healthcare professional (eg, respiratory therapist) at the bedside, employing a standardised consultation and assessment form. The form gathers information on smoking history and readiness to quit. It guides the health professional in the selection and ordering of quit smoking medication, giving practical advice, and registering the patient in the follow-up support programme; (2) pharmacotherapy (primarily nicotine replacement therapy—NRT) is offered to the patient for the duration of their hospital admission and ordered through the hospital pharmacy using standard medication order forms; (3) guidance regarding the use of smoking cessation pharmacotherapy following hospital discharge is provided; (4) a patient education booklet with information for those thinking about quitting, preparing to quit, ready to quit, or wanting to stay smoke-free is provided; (5) enrolment in a telephone follow-up system for 6 months after discharge is offered. The telephone follow-up is conducted using an automated system that places eight programmed calls to smokers on days 3, 14, 30, 60, 90, 120, 150 and 180 after their discharge date. Patients respond to automated questions about their smoking status and their confidence in remaining smoke-free. Their responses serve as a triage tool, and the system flags those who have relapsed to smoking or who may have low confidence in remaining smoke-free. Nurse counsellors who specialise in smoking cessation treatment and relapse prevention monitor the system and call patients who are flagged as experiencing difficulty. The OMSC protocol and follow-up system have been previously described in greater detail.4 5 14

**Usual care**

A number of guidelines exist recommending the integration of tobacco cessation interventions within clinical practices in Canada15 16; however, the large majority of hospitals in Canada do not have in place smoking cessation protocols or programmes. Therefore, the most common alternative to our intervention is usual care, which may consist of the recording of smoking status on the patient chart and possibly the provision of a patient education booklet.

**Model framework**

A decision analytic model was developed using an Excel spreadsheet (Microsoft Corporation, USA). It included smokers hospitalised with AMI, UA, HF and COPD (13 326 in each the usual care and OMSC branches), their RR of continuing to smoke, and the transitions to various states relating to health outcomes among those who continued to smoke versus those who had quit over the 1-year period (figure 1). The following 1-year health states were included: no adverse outcomes, one rehospitalisation, two or more rehospitalisations, or death.

**Data elements**

The data elements used in our model’s base case analysis are listed in table 1 and their sources identified.

**Smoking abstinence rates**

Smoking abstinence rates were obtained from our study dataset. Self-reported 6-month continuous quit rates (ie, patient responded ‘no’ when asked ‘have you used any form of tobacco in the past 6 months?’) had been collected on a sample of smokers who received either usual care (n=369) or OMSC (n=439). They were calculated using intention-to-treat analysis (ie, we assumed that those who were lost to follow-up were still smoking) and were broken down by diagnosis. A 5% relapse rate was applied to our 6-month quit rates in order to estimate 1-year quitting in our model based on a 2008 meta-analysis of relapse by Hughes et al.31 Overall, the 12-month quit rate (95% CI was 17.9% (14.0% to 21.8%) for usual care and 28.5% (24.3% to 32.7%) for the OMSC intervention. Disease-specific rates are presented in table 1.

**Rehospitalisation**

We obtained values for the risk of being readmitted to hospital one or two or more times in the year following the index hospitalisation for each diagnosis using data provided by CIHI. These values were assigned to patients who had quit smoking. For continued smokers, the risk values were multiplied by the following RR of being rehospitalised: 1.21 for AMI or UA7; 1.20 for...
intervention costs

Intervention costs did not include costs related to implementing the programme, but included costs incurred by the hospitals for operating the programme. These costs were based on previous evaluations of the OMSC, and included: (1) personnel costs associated with providing 30 min of bedside intervention ($C20.63 per patient); (2) the average daily cost of NRT ($C2.15 per patient, as determined by the University of Ottawa Heart Institute Department of Pharmacy); (3) telephone follow-up system and programme database management fees ($C10.30 per patient; TelASK Technologies, Ottawa, Ontario, Canada); and, (4) personnel costs associated with 40 min of monitoring of the follow-up system ($C27.24 per patient).

Base case outcomes

Our base case analysis produced the following intermediate outcomes for usual care and OMSC groups: number of quitters, number of rehospitalisations, number of hospital-days, number of deaths, number of life-years, and number of QALYs. The net cost (total rehospitalisation costs saved minus total intervention costs) and intermediate outcomes were used to calculate the cost-effectiveness ratios. Our primary short-term outcome was 1-year cost per QALY gained. Additional 1-year outcomes were: cost per quitter, cost per hospital-day avoided, and cost per death avoided.

Long-term (ie, over the patient’s lifetime) outcomes included lifetime cost per QALY gained and cost per life-year gained (LYG). Mean age and life expectancies were used to calculate total life-years for usual care and OMSC groups. Mean age by diagnosis was obtained from the OMSC database. For long-term QALYs, we multiplied the average life expectancy in each group by the corresponding utility scores.

Sensitivity analyses

Univariate sensitivity analysis

We conducted a series of interviews with hospital decision makers (n=22) and provincial healthcare policy analysts (n=5) to determine what additional intervention components to consider in our sensitivity analysis. The most common component of interest was the addition of 12 weeks of cost-free NRT for patients once they are discharged from hospital. Based on recent reviews evaluating the efficacy of population-based and hospital-based interventions that include NRT, we estimated that the addition of 12 weeks of NRT would increase our programme effectiveness by a relative 58%.

For long-term outcomes, costs and benefits were discounted at 5% in the base case. We used rates of 0% and 3% in the sensitivity analysis as recommended by Canadian guidelines for the economic evaluation of health technologies.

Table 2: Projected cost outcomes of OMSC intervention compared to usual care in patients with AMI, UA, HF and COPD ($ in $C)

<table>
<thead>
<tr>
<th>Cost</th>
<th>Usual care (n=15 326)</th>
<th>OMSC (n=15 326)</th>
<th>Costs (savings) from intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention costs</td>
<td>$10 575</td>
<td>$1 139 070</td>
<td>$1 128 495</td>
</tr>
<tr>
<td>Repeat hospitalisation costs in year following index hospitalisation</td>
<td></td>
<td>$1 139 070</td>
<td>$1 128 495</td>
</tr>
<tr>
<td>AMI</td>
<td>$5 984 453</td>
<td>$5 808 343</td>
<td>($176 110)</td>
</tr>
<tr>
<td>UA</td>
<td>$1 474 391</td>
<td>$1 433 128</td>
<td>($41 263)</td>
</tr>
<tr>
<td>HF</td>
<td>$10 991 834</td>
<td>$10 777 828</td>
<td>($214 007)</td>
</tr>
<tr>
<td>COPD</td>
<td>$26 901 393</td>
<td>$26 289 058</td>
<td>($612 335)</td>
</tr>
<tr>
<td>Total</td>
<td>$45 362 645</td>
<td>$45 447 426</td>
<td>$84 781</td>
</tr>
<tr>
<td>Per patient</td>
<td>$2960</td>
<td>$2965</td>
<td>$5</td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary diseases; HF, heart failure; OMSC, Ottawa model for smoking cessation; UA, unstable angina pectoris.

Probabilistic sensitivity analysis

We performed a probabilistic sensitivity analysis to generate uncertainty in the model using Monte Carlo simulation technique for our primary short-term outcome of 1-year cost per QALY gained as well as for lifetime cost per QALY gained. This is a common method used when economic evaluations are based on patient-level or observational data to handle the fact that data elements or ‘input parameters’ that go into the model are imprecisely estimated from sampled data. In our case, this applies to our input parameters of costs, quit rates, rehospitalisation rates, length of stay values and death rates. Each of these
parameters included a SD or 95% CI which were the distributions used to handle the uncertainty in our model. The uncertainty of all the parameters was assessed simultaneously and was characterised as b distributions (probability between 0 and 1). Our model was evaluated 5000 times, with each simulation involving a random draw from each of the input parameter distributions. In our study, 5000 estimates of costs and QALYs were obtained and were presented by two cost-effectiveness acceptability curves (CEAC)—one for short-term and one for long-term QALYs. The CEACs report the probability that the intervention is cost effective compared to usual care for alternative values of a QALY.

**RESULTS**

**Base case analysis**

**Short-term**

Table 2 presents the cost outcomes of the OMSC intervention compared to usual care by diagnosis. From the hospital payer perspective, providing the OMSC programme to 15 326 smokers with AMI, UA, HF, or COPD would cost an average of $74 per smoker, or $1 139 070 per year. This investment would generate 4689 new quitters and would prevent 116 repeat hospitalisations, 923 hospital days, and 119 deaths in the first year. The base case intermediate outcomes are presented in table 3.

Overall, the intervention resulted in the following 1-year cost-effectiveness ratios: cost per QALY gained of $C1386, cost per quitter of $C20, cost per hospital day avoided of $C103, and cost per death avoided of $C803. The disease-specific and overall cost-effectiveness ratios are summarised in table 4.

**Long term**

The OMSC intervention resulted in an overall lifetime cost per QALY gained of $C61 and cost per LYG of $C36. The OMSC intervention resulted in greater lifetime QALY and life-years for each of the diagnoses. The lifetime QALY gained were 0.31 per smoker with AMI, 0.29 per smoker with UA, 0.15 per smoker with HF, and 0.20 per smoker with COPD. The overall number of life-years gained per smoker was 0.40.

**Sensitivity analyses**

The univariate sensitivity analysis results are presented in table 4. In the base case analysis, quit smoking medications were only provided to the patients during their hospital admission. The provision of 12 weeks of NRT to patients following their hospitalisation increased the per-patient intervention cost by $C486, and produced an overall 1-year cost per QALY gained of $C346, and produced an overall 1-year cost per QALY gained of $C1071.

For the long-term cost-effectiveness ratios, the programme remained cost effective when 0% and 3% discounting was applied.

**DISCUSSION**

Not surprisingly, our results indicate the economic burden to the hospital system of continued smoking is large. Hospitalisation is an opportune time to initiate smoking cessation treatment as smokers are frequent and high cost users of the healthcare system and are often highly motivated to quit smoking during their admission. Smokers would benefit significantly from receiving cessation support while in hospital in terms of being able to quit smoking and reducing their risk of morbidity and mortality. An estimated $C547 million is spent each year in Ontario on hospitalisations for AMI, UA, HF and COPD alone. Our study estimates that provision of the OMSC intervention to smokers admitted with these issues would represent 0.20% of this cost, yet could result in several individual and health system benefits and, in the case of COPD patients, could result in actual cost savings.

However, there is an apparent expectation of behavioural or preventative interventions, including smoking cessation, to demonstrate that they are cost saving or able to save lives with little

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Usual care (n=15 326)</th>
<th>OMSC (n=15 326)</th>
<th>Outcomes prevented (gained) by intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients who continue to smoke, n</td>
<td>12 657</td>
<td>10 637</td>
<td>2020</td>
</tr>
<tr>
<td>1 year repeat hospitalisations, n</td>
<td>AMI 626</td>
<td>608</td>
<td></td>
</tr>
<tr>
<td>UA 248</td>
<td>241</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF 1096</td>
<td>1074</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD 3054</td>
<td>2985</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total 5024</td>
<td>4908</td>
<td>116</td>
<td></td>
</tr>
<tr>
<td>1 year hospital days, n</td>
<td>AMI 3506</td>
<td>3403</td>
<td></td>
</tr>
<tr>
<td>UA 1016</td>
<td>988</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF 10 631</td>
<td>10 424</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD 25 655</td>
<td>25 071</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total 40 808</td>
<td>39 886</td>
<td>923</td>
<td></td>
</tr>
<tr>
<td>1 year mortality, n</td>
<td>AMI 687</td>
<td>644</td>
<td></td>
</tr>
<tr>
<td>UA 124</td>
<td>117</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF 1197</td>
<td>1156</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD 541</td>
<td>515</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total 2550</td>
<td>2431</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>Life years, n</td>
<td>AMI 40 703</td>
<td>41 701</td>
<td></td>
</tr>
<tr>
<td>UA 9975</td>
<td>10 282</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF 8616</td>
<td>9015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD 42 497</td>
<td>43 479</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total 101 791</td>
<td>104 476</td>
<td>(2685)</td>
<td></td>
</tr>
<tr>
<td>QALYs (1 year), n</td>
<td>AMI 2584</td>
<td>2612</td>
<td></td>
</tr>
<tr>
<td>UA 716</td>
<td>722</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF 1059</td>
<td>1074</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD 2816</td>
<td>2835</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total 7175</td>
<td>7244</td>
<td>(69)</td>
<td></td>
</tr>
<tr>
<td>QALYs (lifetime), n</td>
<td>AMI 21 701</td>
<td>22 383</td>
<td></td>
</tr>
<tr>
<td>UA 5741</td>
<td>5920</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF 7189</td>
<td>7353</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD 23 386</td>
<td>23 911</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total 58 017</td>
<td>59 568</td>
<td>(1551)</td>
<td></td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; HF, heart failure; OMSC, Ottawa model for smoking cessation; QALY, quality adjusted life year; UA, unstable angina pectoris.
investment. By contrast, this requirement does not exist to nearly the same extent when it comes to other medical or procedural interventions for chronic diseases, for instance, treatments for hyperlipidaemia or vascular surgeries. Given the known benefits of smoking cessation on morbidity and mortality, it is our opinion that cessation interventions should be adopted regardless of their ability to save money. If smoking cessation interventions are indeed cost saving, this should be seen simply as a favourable consequence of helping people to quit.

Results as compared to other studies
An earlier investigation revealed that a nurse-led smoking cessation intervention for patients hospitalised for AMI cost $C220 per LYG in 1991 US dollars (approximately $C628 per LYG in current Canadian dollars). In that study, the intervention was estimated to reduce smoking by 26%, more than twice as much as our estimate. We believe our estimate of the effect of the OMSC intervention on quitting is a more accurate reflection of what can be achieved in 2012. More recently, Ladapo et al projected the cost-effectiveness of smoking cessation interventions for a hypothetical US cohort of 327 600 smokers hospitalised with AMI employing in-hospital counselling and follow-up telephone calls from a nurse after discharge, but did not include the use of pharmacotherapy in the base case; their programme would cost $C540 per quitter and $C4350 per LYG. Comparatively, the OMSC cost-effectiveness ratios for smokers with AMI of $C99 per quitter and $C196 per LYG can be considered highly appealing.

Our long-term cost-effectiveness ratios are also highly attractive when compared to several other interventions routinely used to treat patients with smoking-related conditions (or their sequelae), including: b-blocker use after AMI (≈$C10 000 per LYG); inhaled corticosteroids for treatment of COPD (≈$C30 000 per LYG) in 2012. More recently, Ladapo et al projected the cost-effectiveness of smoking cessation interventions for a hypothetical US cohort of 327 600 smokers hospitalised with AMI employing in-hospital counselling and follow-up telephone calls from a nurse after discharge, but did not include the use of pharmacotherapy in the base case; their programme would cost $C540 per quitter and $C4350 per LYG. Comparatively, the OMSC cost-effectiveness ratios for smokers with AMI of $C99 per quitter and $C196 per LYG can be considered highly appealing.

Our long-term cost-effectiveness ratios are also highly attractive when compared to several other interventions routinely used to treat patients with smoking-related conditions (or their sequelae), including: b-blocker use after AMI (≈$C10 000 per LYG); inhaled corticosteroids for treatment of COPD (≈$C30 000 per LYG).
consequences accrue over time.72 32 93 0

It might be speculated that patients who quit smoking after hospitalisation are sicker than those who continue to smoke. Because our risk estimates were drawn from observational data, they likely underestimate the harms of continued smoking. We did not consider the effects of quitting smoking on preventing other important smoking-attributable illnesses (eg, cancers, stroke, peripheral vascular disease, other respiratory diseases, and other cardiac diseases). We chose to examine costs and outcomes specifically related to hospitalisations. There is a dearth of information when it comes to the impact of smoking cessation on other important healthcare system costs and savings, for instance, those related to emergency department, specialty-care and primary-care visits. Future studies should examine a wider array of healthcare impacts, and consider a societal perspective that would also take into account productivity gains or losses. Quitting smoking has been associated with gains in societal productivity; it is thought that the inclusion of such information would further improve an understanding of the cost-effectiveness of the intervention.43 44 Our study only examined costs and benefits that occurred in the first year. Evidence suggests that patients who quit may be at reduced risk for hospitalisation, morbidity and death in subsequent years, as the benefits of cessation accrue over time.7 24 29 30

CONCLUSIONS

Due to population ageing and the costly burden of chronic diseases that exists globally, hospitals and healthcare payers are searching for cost-effective solutions, including primary and secondary prevention strategies. Implementation of the OMS hospital-initiated intervention for smoker-patients appears to be a highly cost-effective option from the hospital payer’s perspective. Important consideration is the relatively low intervention cost compared to the reduction in costs related to readmissions for illnesses associated with continued smoking.

Study limitations

Our study has several limitations. We did not model dynamic changes in smoking status that can occur over time, nor did we have data concerning effects of the OMS on quit rates longer than 12 months after hospitalisation. Only a small percentage of smokers (3–5%), however, spontaneously quit smoking, and smokers who are abstinent at 12 months have a 95% likelihood of being smoke-free at 24-month follow-up.42

We did not account for smoking cessation interventions that may have occurred outside of the hospital in either group. It is possible that smokers may have received support that would have generated additional costs; however, we did not model these potential costs in our current study. Before applying our results, readers need to consider that four distinct patient populations were examined in our model, and results may not be transferable to other patient populations. We examined a moderately intensive intervention provided in an acute care setting, and application of our data to other interventions or healthcare settings should be done with caution. Further, usual care or the most common alternatives available in other countries may differ from the usual care scenario in Canada that was applied in our model.

Some of our data elements, for instance, our RR of rehospitalisation and death and our utility score estimates, were drawn from older studies, and in the case of COPD risks, a longitudinal observational trial.19 20 22 27 30 We included distributions for all input parameters except utility scores and life expectancies as they were unavailable in the studies we used; therefore, we were unable to assess the uncertainty of these parameters in our probabilistic sensitivity analysis.

Acknowledgements The authors would like to acknowledge the contributions of Laura Jones of the University of Ottawa Heart Institute for her assistance in data gathering and management. In addition, we would like to thank the peer-reviewers for their thoughtful suggestions which, we feel, have enhanced the current version.

Contributors RDR and KAM conceived the study. KAM, HVN and BP compiled the sources and developed and analysed the economic model with the guidance of DC. DC advised and reviewed the data and completed the sensitivity analyses. KAM and RDR drafted the manuscript. KAM, DC, DM, HVN, BP, ALP and RDR contributed to analysis and outcome planning and to the writing, reviewing, and editing of the final manuscript. KAM is the guarantor.

Funding This project was supported by a Contribution Agreement between the University of Ottawa Heart Institute and the Ontario Ministry of Health and Long Term Care. All authors declare independence from the funder. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests ALP has served as a consultant to Pfizer, GlaxoSmithKline, Johnson & Johnson and Amgen; and, received educational and research support from Pfizer & Johnson & Johnson. RDR has received research support, speaker and consultation fees from Pfizer.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Unpublished data from the study, specifically deidentified and economic model data, can be made available to editors and reviewers upon request to corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
Research paper


13 Canadian Institute for Health Information. Total number of acute inpatient hospitalizations for each of the five conditions as the MRDx, in Ontario, by fiscal year. Data provided by Division Support Services, 2012.


